Department of Psychiatry and Psychology, Mayo Clinic, Albert Lea, Minnesota, USA.
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Am J Addict. 2024 May;33(3):269-282. doi: 10.1111/ajad.13517. Epub 2024 Jan 25.
Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) have evidence for their potential in the treatment of substance use disorders (SUD). Medication for addiction treatment (MAT) is underutilized and not always effective. We identified randomized controlled trials (RCTs) and case studies that evaluated the effectiveness of TMS or tDCS used concurrently with MAT in SUD treatment.
A systematic review of published literature following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was conducted on 6/1/2023 by a medical librarian. Craving-related scales were extracted for an effect size calculation. The Physiotherapy Evidence Database (PEDro) scale assessed study quality.
Eight studies (7 RCT, 1 case) including 253 individuals were published from 2015 to 2022, 5 of which had available data for meta-analysis. TMS or tDCS combined with MAT significantly reduced craving-related measures relative to sham stimulation (Hedges' g = -0.42, confidence interval: -0.73 to -0.11, p < .01). Opioid use disorder, methadone, and the dorsolateral prefrontal cortex were the most commonly studied SUD, MAT, and target region.
Our results show a significant effect; however, is limited by a small number of studies with heterogeneous methodology across intervention methods and SUDs. Additional trials are needed to fully assess the clinical impact and mechanisms of combined brain stimulation and pharmacotherapy. We discuss a possible mechanism for synergism from these treatment combinations.
Adds the first systematic review of combination treatment with TMS or tDCS and MAT in SUD patients to the literature and estimates its overall effect size.
经颅磁刺激(TMS)和经颅直流电刺激(tDCS)在治疗物质使用障碍(SUD)方面具有潜在的应用价值。用于成瘾治疗的药物(MAT)的利用率较低,且并非总是有效。我们鉴定了同时使用 MAT 治疗 SUD 的 TMS 或 tDCS 的有效性的随机对照试验(RCT)和病例研究。
一名医学图书管理员按照系统评价和荟萃分析的首选报告项目(PRISMA)指南,于 2023 年 6 月 1 日对已发表的文献进行了系统综述。提取与渴望相关的量表以进行效应量计算。物理治疗证据数据库(PEDro)量表评估了研究质量。
2015 年至 2022 年共发表了 8 项研究(7 项 RCT,1 项病例研究),包括 253 名个体,其中 5 项研究有可用于荟萃分析的数据。TMS 或 tDCS 联合 MAT 与假刺激相比,显著降低了与渴望相关的测量值(Hedges'g=-0.42,置信区间:-0.73 至-0.11,p<0.01)。阿片类药物使用障碍、美沙酮和背外侧前额叶皮层是最常研究的 SUD、MAT 和目标区域。
我们的结果表明存在显著效果,但受到干预方法和 SUD 方面具有异质性方法学的少数研究的限制。需要进一步的试验来全面评估联合脑刺激和药物治疗的临床影响和机制。我们讨论了这些治疗组合协同作用的可能机制。
该研究是首次对 TMS 或 tDCS 联合 MAT 治疗 SUD 患者的文献进行了系统评价,并估计了其总体效应大小。